Pfizer and BioNTech halted their COVID-19 vaccine trial for healthy adults in their 50s and 60s last week. The reason is not a safety signal or an efficacy problem. It is that almost nobody qualified.
More than 80 percent of people who wanted to enroll failed the pre-screening requirements, leaving the companies unable to generate the data the FDA demanded before it will approve an updated shot for this age group. Enrollment closed on March 6, 2026. Pfizer sent a letter to trial investigators on March 30 saying surveillance for COVID illness would stop after April 3.
The trial was designed to answer a question that may now go unanswered indefinitely. The FDA's top vaccines regulator, Vinay Prasad, wrote a policy in May 2025 requiring placebo-controlled trials for COVID vaccines in healthy adults under 65 before annual approvals could be granted. That policy was built on the assumption that enough people would enroll in a trial where half the participants get a placebo and the other half get the updated vaccine. Healthy adults in their 50s and 60s are not lining up for that deal.
Prasad, who as director of the FDA's Center for Biologics Evaluation and Research (CBER) oversees vaccine approvals, will leave the agency at the end of April. The trial his policy required will never produce the data he asked for. The policy is now orphaned: no company has successfully run the study it mandates, and the regulator who wrote it will be gone before the data could have arrived regardless.
The virus continues to cause an estimated 8,000 to 12,000 deaths per year among adults aged 50 to 64, according to CDC data. That is a fraction of the pandemic toll, but it is not zero, and it is a population that stands to benefit from regularly updated vaccines matched to circulating strains. The policy that made this trial necessary also made it nearly impossible to run. The FDA required that trial participants have no chronic conditions such as hypertension or diabetes, despite the fact that these are common in the 50-64 age group. Only about 18 percent of Americans received a COVID booster during the 2025-26 season, according to CDC data. A population that largely did not show up for a free booster is not going to show up for a trial where they might get a placebo instead.
Moderna is running a similar 30,000-person study for the same age group and is facing the same recruitment problem, according to sources at four trial sites who spoke to Reuters. That study is expected to conclude in June 2027, assuming enrollment holds.
Dr. Jesse Goodman, a former FDA chief scientist, put the stakes plainly in comments to Reuters. Without the data, he said, there probably just will not be a presentation at the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC). And without that presentation, there may not be a specific approval pathway for updated vaccines in this age group. Updated shots would continue to reach older and younger populations under existing pathways, while healthy adults in their 50s and 60s fall through a gap created by a policy that was technically correct and practically unworkable.
The policy's logic was not unreasonable on its face. After several years of COVID vaccines being widely available and the virus becoming endemic, the benefit of repeated annual shots for healthy adults was genuinely uncertain. Prasad and FDA Commissioner Marty Makary wrote in the New England Journal of Medicine in May 2025 that this benefit was unclear and that formal clinical trials were needed to establish it. Placebo-controlled trials are the gold standard for measuring vaccine efficacy. The problem is that gold standards do not matter if you cannot recruit enough participants to use them.
This is not the first time a clinical trial design has collided with how adults actually behave. The difference here is that the regulatory deadline is now a personal one: Prasad will not be at the agency to see whether his policy works or fails.
What happens next is unclear. The FDA could revise its requirements, accept different trial designs, or leave the policy on the books while the problem compounds. Moderna will either solve its recruitment problem in the next several months or face the same halt Pfizer and BioNTech reached. Adults in their 50s and 60s who want an updated COVID vaccine will continue to rely on a system that was never designed to serve them specifically. COVID is still killing thousands of them every year, and the only regulatory pathway built to change that may close before anyone uses it.